Clinical Trials
68 trialsA Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
SURGE Therapeutics
Comparison of CT and MR (VI-RADS) Imaging for Local Bladder Cancer Staging
Oslo University Hospital
SURF302
Tyra Biosciences, Inc
ADVANCED-2
Protara Therapeutics
A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)
Memorial Sloan Kettering Cancer Center
Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment
Memorial Sloan Kettering Cancer Center
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
Janssen Research & Development, LLC
MoonRISe-1
Janssen Research & Development, LLC
A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer
Roswell Park Cancer Institute
MoonRISe-3
Janssen Research & Development, LLC
Nova-sTAR
Janssen Research & Development, LLC
ReplaceCysto
White River Junction Veterans Affairs Medical Center
TroFuse-027
Merck Sharp & Dohme LLC
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
enGene, Inc.
TVNIM-AFU
Association Francaise d'Urologie
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
Lepu Biopharma Co., Ltd.
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
Pfizer
CISTO2
University of Washington
Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC
University of Iowa
ADAPT-BLADDER
Hoosier Cancer Research Network
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
Aura Biosciences
ENHANCE
Hoosier Cancer Research Network
GAIN-BCG
Alliance for Clinical Trials in Oncology
INTerpath-011
Merck Sharp & Dohme LLC
ENAiBLE
Photocure
In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial
Mayo Clinic
ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG
ImmunityBio, Inc.
MiLUT
University of Zurich
PRO-GAG
BLAD-HYA Group
Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer
Ohio State University Comprehensive Cancer Center
PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
University of California, Davis
The Guiding Value of Liquid Biopsy Based on Urinary Tumor DNA/RNA in the Second Transurethral Resection of High-risk Non-muscle Invasive Bladder Cancer
Tianjin Medical University Second Hospital
Hydeal Cyst
Istituto Oncologico Veneto IRCCS
SPICE
University of Aarhus
CUT-less
University of Roma La Sapienza
BLCCR
Photocure
BicaBCa
CHU de Quebec-Universite Laval
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
Theralase® Technologies Inc.
Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG
Johns Hopkins University
COBRA-NMIBC
Aarhus University Hospital
Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer
Lahey Clinic
A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy
Ractigen Therapeutics.
A Phase I Intravesical PPM Therapy for NMIBC
VA Office of Research and Development
Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC)
University of Texas Southwestern Medical Center
A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer
Suzhou Forlong Biotechnology Co., Ltd
A Study Comparing the Necessity of a Second Transurethral Resection in High-Risk Non-Muscle-Invasive Bladder Cancer Patients With Negative Results From Post-Initial Resection Urine Genome-Wide Low-Depth Sequencing
The First Affiliated Hospital with Nanjing Medical University
HGNMIBC
Relmada Therapeutics, Inc.
COBRA
Medical University of Vienna
Trop2-targeting NIR-II Molecular Probe for Guided Identification of Non-Muscle-Invasive Bladder Cancer
Yunnan Cancer Hospital
A Multicenter Prospective Cohort Study on Monitoring Recurrence of Urothelial Carcinoma Based on Detection of Urinary Microscopic Residual Disease (MRD)
Peking University First Hospital